1. Home
  2. BMEA vs VTGN Comparison

BMEA vs VTGN Comparison

Compare BMEA & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • VTGN
  • Stock Information
  • Founded
  • BMEA 2017
  • VTGN 1998
  • Country
  • BMEA United States
  • VTGN United States
  • Employees
  • BMEA N/A
  • VTGN N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • VTGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • BMEA Health Care
  • VTGN Health Care
  • Exchange
  • BMEA Nasdaq
  • VTGN Nasdaq
  • Market Cap
  • BMEA 65.8M
  • VTGN 59.8M
  • IPO Year
  • BMEA 2021
  • VTGN N/A
  • Fundamental
  • Price
  • BMEA $1.57
  • VTGN $2.92
  • Analyst Decision
  • BMEA Strong Buy
  • VTGN
  • Analyst Count
  • BMEA 10
  • VTGN 0
  • Target Price
  • BMEA $21.00
  • VTGN N/A
  • AVG Volume (30 Days)
  • BMEA 957.5K
  • VTGN 506.3K
  • Earning Date
  • BMEA 08-12-2025
  • VTGN 08-07-2025
  • Dividend Yield
  • BMEA N/A
  • VTGN N/A
  • EPS Growth
  • BMEA N/A
  • VTGN N/A
  • EPS
  • BMEA N/A
  • VTGN N/A
  • Revenue
  • BMEA N/A
  • VTGN $486,000.00
  • Revenue This Year
  • BMEA N/A
  • VTGN $23.83
  • Revenue Next Year
  • BMEA N/A
  • VTGN $660.39
  • P/E Ratio
  • BMEA N/A
  • VTGN N/A
  • Revenue Growth
  • BMEA N/A
  • VTGN N/A
  • 52 Week Low
  • BMEA $1.29
  • VTGN $1.90
  • 52 Week High
  • BMEA $13.07
  • VTGN $3.79
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 37.40
  • VTGN 62.58
  • Support Level
  • BMEA $1.72
  • VTGN $2.25
  • Resistance Level
  • BMEA $1.75
  • VTGN $3.33
  • Average True Range (ATR)
  • BMEA 0.11
  • VTGN 0.25
  • MACD
  • BMEA -0.02
  • VTGN 0.03
  • Stochastic Oscillator
  • BMEA 9.20
  • VTGN 62.04

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Share on Social Networks: